All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

361

2015 to 2026

Breakthrough

146

Accelerated

99

Priority review

361

Orphan

229

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
2015196
2016123
2017229
20183212
2019247
2020246
2021288
20221511
20232311
2024219
2025199
2026238

361 approvals

Newest first. Hover a badge for what it means.

  • Sunharbo (Asundexian) · Bayer HealthcareNov 9, 2026
    Original approval · NDA 221291NovelPriority reviewApproval letter

    To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack

  • Hibsago (Bepirovirsen Sodium) · GlaxosmithklineOct 20, 2026
    Original approval · NDA 221276NovelPriority reviewApproval letter

    To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy

  • Hovilpri (Pritelivir Mesylate) · Aicuris Anti-InfectOct 9, 2026
    Original approval · NDA 221154NovelPriority reviewApproval letter

    To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies

  • Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
    Original approval · NDA 220963NovelPriority reviewOrphanApproval letter

    To treat peripheral thyrotoxicosis in patients with MCT8 deficiency

  • Atebrioz (Zilurgisertib Fumarate) · MirumSep 25, 2026
    Original approval · NDA 221198NovelPriority reviewOrphanApproval letter

    To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva

  • Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
    Original approval · NDA 220425NovelPriority reviewOrphanApproval letter

    To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

  • Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
    Original approval · BLA 761463NovelPriority reviewOrphanApproval letter

    To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment

  • Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
    Original approval · NDA 218592NovelPriority reviewOrphanApproval letter

    To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations

  • Zanvastro (Zilganersen Sodium) · Ionis Pharms INCSep 3, 2026
    Original approval · NDA 220210NovelPriority reviewOrphanApproval letter

    To treat Alexander disease in pediatric and adult patients

  • Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
    Original approval · NDA 220605NovelPriority reviewOrphanApproval letter

    To treat erythrocytosis in adults with polycythemia vera

  • Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
    Original approval · NDA 220106NovelPriority reviewOrphanApproval letter

    To treat dermatomyositis in adults

  • Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
    Original approval · NDA 220910NovelPriority reviewOrphanApproval letter

    To treat metastatic pancreatic cancer

  • Pasatru (Garetosmab-Grts) · Regeneron Pharmaceuticals, INCAug 19, 2026
    Original approval · BLA 761508NovelPriority reviewOrphanApproval letter

    To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva

  • Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
    Original approval · NDA 221075NovelPriority reviewOrphanApproval letter

    To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent

  • Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
    Original approval · NDA 220860NovelPriority reviewOrphanApproval letter

    To treat narcolepsy type 1

  • Simtriyo (Centanafadine Hydrochloride) · OtsukaJul 24, 2026
    Original approval · NDA 218145NovelPriority reviewApproval letter

    To treat attention-deficit hyperactivity disorder

  • Lipfendra (Enlicitide Decanoate) · MsdJul 15, 2026
    Original approval · NDA 220848NovelPriority reviewApproval letter

    To reduce low-density lipoprotein cholesterol

  • Revtorpyk (Gedatolisib) · CelcuityJul 14, 2026
    Original approval · NDA 219908NovelPriority reviewApproval letter

    In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting

  • Trutakna (Atacicept-Vymj) · Vera Therapeutics Inc.Jul 7, 2026
    Original approval · BLA 761486NovelPriority reviewApproval letter

    To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression

  • Lumvoa (Veligrotug-Vvze) · Viridian Therapeutics INCJun 26, 2026
    Original approval · BLA 761530NovelBreakthrough therapyPriority reviewApproval letter

    To treat thyroid eye disease

  • Utebzi (Tebipenem Pivoxil Hydrobromide) · GlaxosmithklineJun 17, 2026
    Original approval · NDA 215960NovelPriority reviewApproval letter

    To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

  • Zaynich (Cefepime Hydrochloride, Zidebactam) · Wockhardt Bio AGMay 29, 2026
    Original approval · NDA 220787NovelPriority reviewApproval letter

    To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms

  • Decnupaz (Pivekimab Sunirine-Pvzy) · Abbvie INCMay 27, 2026
    Original approval · BLA 761460NovelPriority reviewOrphanApproval letter

    To treat adults with blastic plasmacytoid dendritic cell neoplasm

  • Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026
    Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis

  • Baxfendy (Baxdrostat) · Astrazeneca AbMay 15, 2026
    Original approval · NDA 219878NovelPriority reviewApproval letter

    To treat hypertension in combination with other antihypertensive drugs

  • Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026
    Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor

  • Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026
    Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

  • Icotyde (Icotrokinra Hydrochloride) · Janssen BiotechMar 17, 2026
    Original approval · NDA 220149NovelPriority reviewApproval letter

    To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy

  • Yuviwel (Navepegritide) · AscendisFeb 27, 2026
    Original approval · NDA 219164NovelAccelerated approvalPriority reviewOrphanApproval letter

    To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses

  • Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026
    Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

  • Zycubo (Copper Histidinate) · Sentynl Theraps INCJan 12, 2026
    Original approval · NDA 211241NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat Menkes disease

  • Yartemlea (Narsoplimab-Wuug) · Omeros CorpDec 23, 2025
    Original approval · BLA 761152NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

  • Nuzolvence (Zoliflodacin) · Entasis TherapDec 12, 2025
    Original approval · NDA 219491NovelPriority reviewApproval letter

    To treat uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae

  • Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTDNov 25, 2025
    Original approval · BLA 761434NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression

  • Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025
    Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

  • Komzifti (Ziftomenib) · KuraNov 13, 2025
    Original approval · NDA 220305NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options

  • Kygevvi (Doxecitine, Doxribtimine) · Ucb INCNov 3, 2025
    Original approval · NDA 219792NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

  • Jascayd (Nerandomilast) · Boehringer IngelheimOct 7, 2025
    Original approval · NDA 218764NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat idiopathic pulmonary fibrosis

  • Rhapsido (Remibrutinib) · NovartisSep 30, 2025
    Original approval · NDA 218436NovelPriority reviewApproval letter

    To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment

  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp DohmeSep 19, 2025
    Original approval · BLA 761467NovelAccelerated approvalPriority reviewApproval letter

    To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab

  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp DohmeSep 19, 2025
    Original approval · BLA 761467NovelPriority reviewApproval letter

    To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab

  • Forzinity (Elamipretide Hydrochloride) · Stealth BiotherapsSep 19, 2025
    Original approval · NDA 215244NovelAccelerated approvalPriority reviewOrphanApproval letter

    To improve muscle strength in patients with Barth syndrome weighing at least 30 kg

  • Brinsupri (Brensocatib) · Insmed INCAug 12, 2025
    Original approval · NDA 217673NovelBreakthrough therapyPriority reviewApproval letter

    To treat non-cystic fibrosis bronchiectasis

  • Hernexeos (Zongertinib) · Boehringer IngelheimAug 8, 2025
    Original approval · NDA 219042NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy

  • Modeyso (Dordaviprone Hydrochloride) · ChimerixAug 6, 2025
    Original approval · NDA 219876NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy

  • Lynozyfic (Linvoseltamab-Gcpt) · Rengeneron Pharmaceuticals, Inc.Jul 2, 2025
    Original approval · BLA 761400NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody

  • Zegfrovy (Sunvozertinib) · DizalJul 2, 2025
    Original approval · NDA 219839NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy

  • Datroway (Datopotamab Deruxtecan-Dlnk) · Daiichi Sankyo INCJun 23, 2025
    Original approval · BLA 761464NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
  • Yeztugo (Lenacapavir Sodium) · Gilead Sciences INCJun 18, 2025
    Original approval · NDA 220020NovelBreakthrough therapyPriority reviewApproval letter
  • Yeztugo (Lenacapavir, Lenacapavir Sodium) · Gilead Sciences INCJun 18, 2025
    Original approval · NDA 220018NovelBreakthrough therapyPriority reviewApproval letter
Page 1 of 8Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.